Editorially reviewed by Dr Fatimah Khan, registered with the Pakistan Medical and Dental Council (PMDC no. 104595-P). Editorial medical reviewer; does not prescribe or review patient assessments.
Review details
Review recorded:
Review scope: This article edition.
Editorial reviewer for Prescrivia. Editorial review does not establish participation in patient consultations.
Clinical review does not replace individual medical advice. Prescrivia is a technology intermediary; independent doctors make clinical decisions.
Legal review: Qualified review pending.
Language review: Qualified review pending.
Source and review
Source published:
Attributed source update:
Text edited:
Editorial role: Editorial team. This description does not establish an individual credential or clinical review of this edition.
Read our editorial policy and corrections. Edit dates and source descriptions do not establish qualified review.
What is celecoxib used for?
Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) that selectively inhibits the COX-2 enzyme. It can reduce pain and inflammation. The UK Celebrex product information lists adult osteoarthritis, rheumatoid arthritis and ankylosing spondylitis as indications.
An authorisation for a particular product does not establish the same indications for every presentation or country. Acute-pain uses described in a US Celebrex label should not be copied into a universal European dosing guide.
Why a single “usual maximum” is misleading
Dose selection depends on the condition, response and health risks. The UK product information gives condition-specific regimens and a maximum recommended daily amount of 400 mg; that limit is not the dose everyone should take.
The recommended amount can differ between arthritis conditions. Follow the actual prescription rather than selecting or increasing a dose yourself, and ask when response and continuing need will be reassessed.
The underlying principle is the lowest effective dose for the shortest appropriate duration.
Stomach benefit does not mean risk-free treatment
COX-2 selectivity does not eliminate ulcers or gastrointestinal bleeding. Nor does a comparison trial establish that celecoxib has no cardiovascular risk for every patient, dose or duration. The UK product information and US label both retain important safety warnings.
Before prescribing, a clinician needs to review:
- Previous ulcers, bleeding or NSAID reactions.
- Heart or circulation conditions and blood pressure.
- Kidney or liver problems.
- Pregnancy or breastfeeding.
- Other medicines, including aspirin, other NSAIDs and anticoagulants.
Do not stop prescribed low-dose aspirin on the basis of an article; ask the prescriber to review the combination. Combining pain medicines can change bleeding, kidney and interaction risks.
Side effects and urgent symptoms
Indigestion, abdominal discomfort, headache and fluid retention can occur. Chest pain, stroke-like symptoms, gastrointestinal bleeding, a severe blistering rash or breathing difficulty need urgent medical attention. The leaflet for your actual product gives the fuller list and action instructions.
A useful review question
Ask which symptom is being treated and how benefit will be measured. If the medicine is not helping, increasing it yourself is not a safe substitute for review.
Our medicine-access safety guide explains checks before using an online service. Prescrivia is an intermediary; independent clinicians assess suitability and licensed pharmacies dispense where appropriate. No medicine, access or outcome is guaranteed.
General information only, not medical advice. Follow the leaflet for your actual product and discuss decisions with a qualified clinician. See the current clinical, legal and language review statuses for this edition.
Sources
- Viatris UK Celebrex SmPC: adult arthritis indications, condition-specific dose selection and maximum, cardiovascular and gastrointestinal precautions.
- US manufacturer Celebrex label: cardiovascular and gastrointestinal warnings and the limits of transferring indications between countries.
Sources checked online on 6 October 2026. Country-specific guidance does not establish availability or prescribing rules throughout Europe.